T1	PROC 51 85	evaluar la seguridad y efectividad
T2	CHEM 113 123	Lurasidona
#1	AnnotatorNotes T2	C2003424; lurasidone; Organic Chemical · Pharmacologic Substance
T3	PROC 165 172	placebo
#2	AnnotatorNotes T3	C0032042; Placebos; Therapeutic or Preventive Procedure
T4	DISO 205 218	esquizofrenia
#3	AnnotatorNotes T4	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T5	PROC 242 340	ESTUDIO MULTICÉNTRICO, DE DOSIS FIJA, CONTROLADO CON PLACEBO, DOBLE CIEGO, PARALELO Y ALEATORIZADO
T6	PROC 359 393	EVALUAR LA EFICACIA Y LA SEGURIDAD
#4	AnnotatorNotes T6	C0511730; Identify product efficacy and safety issues; Health Care Activity
T7	CHEM 400 410	LURASIDONA
#5	AnnotatorNotes T7	C2003424; lurasidone; Organic Chemical · Pharmacologic Substance
T8	DISO 439 452	ESQUIZOFRENIA
#6	AnnotatorNotes T8	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T9	DISO 476 489	Esquizofrenia
#7	AnnotatorNotes T9	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T10	PROC 580 591	diagnóstico
#8	AnnotatorNotes T10	C0011900; Diagnosis; Diagnostic Procedure
T11	DISO 604 617	esquizofrenia
#9	AnnotatorNotes T11	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T12	PROC 661 672	diagnóstico
#10	AnnotatorNotes T12	C0011900; Diagnosis; Diagnostic Procedure
T13	DISO 679 692	esquizofrenia
#11	AnnotatorNotes T13	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T14	DISO 719 739	trastornos afectivos
#12	AnnotatorNotes T14	C0525045; Mood Disorders; Mental or Behavioral Dysfunction | C1291710; Disturbance in affect; Mental or Behavioral Dysfunction
T15	DISO 742 755	esquizofrenia
#13	AnnotatorNotes T15	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T16	DISO 830 838	síndrome
#14	AnnotatorNotes T16	C0039082; Syndrome; Disease or Syndrome
T17	PROC 976 987	diagnóstico
#15	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	DISO 1022 1035	esquizofrenia
#16	AnnotatorNotes T18	C0036341; Schizophrenia; Mental or Behavioral Dysfunction
T19	PROC 1072 1083	tratamiento
#17	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	PROC 1153 1164	diagnóstico
#18	AnnotatorNotes T20	C0011900; Diagnosis; Diagnostic Procedure
T21	DISO 1175 1189	retraso mental
#19	AnnotatorNotes T21	C0025362; Mental Retardation; Mental or Behavioral Dysfunction | C3714756; Intellectual Disability; Mental or Behavioral Dysfunction
T22	DISO 1191 1220	síndrome neuroléptico maligno
#20	AnnotatorNotes T22	C0027849; Neuroleptic Malignant Syndrome; Disease or Syndrome
T23	DISO 1233 1254	trastorno neurológico
#21	AnnotatorNotes T23	C0027765; nervous system disorder; Disease or Syndrome
T24	DISO 1256 1275	traumatismo craneal
#22	AnnotatorNotes T24	C4324307; Skull trauma; Injury or Poisoning
T25	DISO 1294 1321	enfermedad médica inestable
T26	Date 13 17	2013
T27	Dose 125 130	40 mg
T28	Frequency 130 134	/dia
T29	Dose 137 142	80 mg
T30	Frequency 142 146	/dia
T31	Dose 268 278	DOSIS FIJA
#23	AnnotatorNotes T31	C5548493; Fixed dose; Quantitative Concept
T32	Duration 344 353	6 SEMANAS
T34	LIVB 516 541	Sujetos varones o mujeres
#24	AnnotatorNotes T34	C0681850; Study Subject; Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T36	Age 542 557	de 13 a 17 años
T38	LIVB 761 782	niños en edad escolar
#25	AnnotatorNotes T38	C0260267; School child; Age Group
T40	Neg_cue 1015 1017	no
T41	Duration 1087 1098	los 3 meses
T42	LIVB 1126 1133	sujetos
#26	AnnotatorNotes T42	C0681850; Study Subject; Group
T43	Date 1165 1171	actual
T44	LIVB 188 200	adolescentes
#27	AnnotatorNotes T44	C0205653; Adolescent (age group); Age Group
T45	LIVB 414 434	SUJETOS ADOLESCENTES
#28	AnnotatorNotes T45	C0681850; Study Subject; Group + C0205653; Adolescents; Age Group
T46	PHYS 1183 1189	mental
#29	AnnotatorNotes T46	C0229992; Psyche structure; Mental Process
T33	ANAT 1268 1275	craneal
#30	AnnotatorNotes T33	C0037303; Bone structure of cranium; Body Part, Organ, or Organ Component | C1279062; Entire cranium; Body Part, Organ, or Organ Component
T37	PROC 901 906	CGI-S
#31	AnnotatorNotes T37	C5396527; Assessment using Children's Global Assessment Scale; Health Care Activity (?)
A1	Population_data T44 Age
A2	Population_data T45 Age
A3	Population_data T38 Age
A4	Assertion T18 Negated
A5	Status T21 History_of
A6	Status T22 History_of
A7	Status T23 History_of
A8	Status T24 History_of
A9	Status T25 History_of
#32	AnnotatorNotes T43	C0521116; Current (present time); Temporal Concept 
T35	CONC 819 858	Escala del síndrome positivo y negativo
#33	AnnotatorNotes T35	C4086747; Positive and Negative Syndrome Scale Clinical Classification; Intellectual Product
T39	CONC 860 865	PANSS
#34	AnnotatorNotes T39	C4086747; Positive and Negative Syndrome Scale Clinical Classification; Intellectual Product
T47	CONC 1347 1352	PANSS
#35	AnnotatorNotes T47	C4086747; Positive and Negative Syndrome Scale Clinical Classification; Intellectual Product
R1	Has_Dose_or_Strength Arg1:T2 Arg2:T27	
R2	Has_Dose_or_Strength Arg1:T2 Arg2:T29	
R3	Has_Frequency Arg1:T2 Arg2:T28	
R4	Has_Frequency Arg1:T2 Arg2:T30	
R5	Experiences Arg1:T44 Arg2:T4	
R6	Experiences Arg1:T44 Arg2:T2	
R7	Experiences Arg1:T44 Arg2:T3	
R8	Has_Duration_or_Interval Arg1:T7 Arg2:T32	
R9	Has_Dose_or_Strength Arg1:T7 Arg2:T31	
R10	Experiences Arg1:T45 Arg2:T7	
R11	Experiences Arg1:T45 Arg2:T8	
R12	Has_Age Arg1:T34 Arg2:T36	
R13	Experiences Arg1:T34 Arg2:T11	
R14	Experiences Arg1:T34 Arg2:T13	
R15	Experiences Arg1:T34 Arg2:T15	
R16	Experiences Arg1:T38 Arg2:T15	
R17	Experiences Arg1:T38 Arg2:T13	
R18	Experiences Arg1:T38 Arg2:T11	
R19	Has_Age Arg1:T38 Arg2:T36	
T48	CONC 632 641	DSM-IV-TR
#36	AnnotatorNotes T48	C0220952; DSM-IV; Intellectual Product (?)
R20	Used_for Arg1:T48 Arg2:T10	
T49	Quantifier_or_Qualifier 592 600	primario
#37	AnnotatorNotes T49	C0205225; Primary; Qualitative Concept
R21	Has_Quantifier_or_Qualifier Arg1:T10 Arg2:T49	
T50	CONC 707 755	Programa de trastornos afectivos y esquizofrenia
#38	AnnotatorNotes T50	C0683462; Schedule for Affective Disorder and Schizophrenia; Intellectual Product
T51	CONC 784 793	K-SADS-PL
R22	Used_for Arg1:T50 Arg2:T12	
R23	Used_for Arg1:T51 Arg2:T12	
#39	AnnotatorNotes T51	['Schedule for Affective Disorders and Schizophrenia for School-age Children']
T52	Result_or_Value 867 871	≥ 70
R24	Has_Result_or_Value Arg1:T35 Arg2:T52	
R25	Has_Result_or_Value Arg1:T39 Arg2:T52	
T53	Result_or_Value 907 910	≥ 4
R26	Has_Result_or_Value Arg1:T37 Arg2:T53	
T54	PROC 878 887	selección
#40	AnnotatorNotes T54	C0242802; Patient Selection; Research Activity
R27	Overlap Arg1:T35 Arg2:T54	
R28	Overlap Arg1:T39 Arg2:T54	
T55	CONC 893 899	inicio
#41	AnnotatorNotes T55	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R29	Overlap Arg1:T35 Arg2:T55	
R30	Overlap Arg1:T39 Arg2:T55	
T56	CONC 932 938	inicio
#42	AnnotatorNotes T56	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R31	Overlap Arg1:T37 Arg2:T56	
T57	PROC 917 926	selección
#43	AnnotatorNotes T57	C0242802; Patient Selection; Research Activity
R32	Overlap Arg1:T37 Arg2:T57	
R33	Negation Arg1:T40 Arg2:T18	
R34	Overlap Arg1:T19 Arg2:T41	
T58	PROC 1115 1124	selección
#44	AnnotatorNotes T58	C0242802; Patient Selection; Research Activity
R35	After Arg1:T19 Arg2:T58	
T59	CONC 1053 1057	foco
#45	AnnotatorNotes T59	C1285542; Has focus; Functional Concept 
T60	Quantifier_or_Qualifier 1058 1067	principal
#46	AnnotatorNotes T60	C0205225; Primary; Qualitative Concept
R36	Has_Quantifier_or_Qualifier Arg1:T59 Arg2:T60	
R37	Experiences Arg1:T42 Arg2:T21	
R38	Experiences Arg1:T42 Arg2:T46	
R39	Overlap Arg1:T20 Arg2:T43	
R40	Experiences Arg1:T42 Arg2:T22	
R41	Experiences Arg1:T42 Arg2:T23	
R42	Experiences Arg1:T42 Arg2:T24	
R43	Location_of Arg1:T33 Arg2:T24	
R44	Experiences Arg1:T42 Arg2:T25	
T61	Result_or_Value 1353 1358	≥ 120
R45	Has_Result_or_Value Arg1:T47 Arg2:T61	
#47	AnnotatorNotes T25	C4062077; Unstable health condition; Finding
R46	Overlap Arg1:T21 Arg2:T43	
R47	Overlap Arg1:T22 Arg2:T43	
R48	Overlap Arg1:T23 Arg2:T43	
R49	Overlap Arg1:T24 Arg2:T43	
R50	Overlap Arg1:T25 Arg2:T43	
T62	PROC 1365 1374	selección
#48	AnnotatorNotes T62	C0242802; Patient Selection; Research Activity
R51	Overlap Arg1:T47 Arg2:T62	
T63	CONC 1380 1386	inicio
#49	AnnotatorNotes T63	C4684789; Study Start; Temporal Concept | C2349982; Study start time; Temporal Concept
R52	Overlap Arg1:T47 Arg2:T63	
R53	Experiences Arg1:T42 Arg2:T18	
R54	Experiences Arg1:T42 Arg2:T19	
#50	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
T64	Quantifier_or_Qualifier 1276 1281	grave
#51	AnnotatorNotes T64	C1547227; Severe - Severity of Illness Code; Intellectual Product
R55	Has_Quantifier_or_Qualifier Arg1:T24 Arg2:T64	
A10	Experiencer T44 Patient
A11	Experiencer T45 Patient
A12	Experiencer T34 Patient
A13	Experiencer T38 Patient
A14	Experiencer T42 Patient
